Topical Simvastatin as Host-Directed Therapy against Severity of Cutaneous Leishmaniasis in Mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Parihar, Suraj P ^a,b   Hartley, Mary Anne ^c   Hurdayal, Ramona ^a,b,d   Guler, Reto ^a,b   Brombacher, Frank ^a,b  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYDROGEN PEROXIDE; SIMVASTATIN;

ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECT; IMMUNOLOGY; LEISHMANIA MAJOR; MACROPHAGE; METABOLISM; PARASITE; PARASITOLOGY; PHAGOSOME; RESPIRATORY BURST; SEVERITY OF ILLNESS INDEX; SKIN LEISHMANIASIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROGEN PEROXIDE; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MICE, INBRED BALB C; MICE, INBRED C57BL; PARASITES; PHAGOSOMES; RESPIRATORY BURST; SEVERITY OF ILLNESS INDEX; SIMVASTATIN;

EID: 84988027218     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33458     Document Type: Article

References (32)

1. WHO. Leishmania Facts. World Health Organization Report (2015).
2. Croft, S. L., Sundar, S., Fairlamb, A. H. Drug resistance in leishmaniasis. Clin Microbiol Rev 19, 111-126, doi: 10.1128/CMR.19.1.111-126.2006 (2006).
3. Hartley, M. A., Kohl, K., Ronet, C., Fasel, N. The therapeutic potential of immune cross-talk in leishmaniasis. Clin Microbiol Infect 19, 119-130, doi: 10.1111/1469-0691.12095 (2013).
4. Masihi, K. N. Immunomodulators in infectious diseases: panoply of possibilites. International journal of immunopharmacology 22, 1083-1091 (2000).
5. Pucadyil, T. J., Tewary, P., Madhubala, R., Chattopadhyay, A. Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol Biochem Parasitol 133, 145-152 (2004).
6. Endo, A. A gift from nature: the birth of the statins. Nat Med 14, 1050-1052, doi: 10.1038/nm1008-1050 (2008).
7. Bellosta, S., Ferri, N., Bernini, F., Paoletti, R., Corsini, A. Non-lipid-related effects of statins. Ann Med 32, 164-176, doi: 10.3109/07853890008998823 (2000).
8. Ray, K. K. et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 170, 1024-1031, doi:10.1001/archinternmed.2010.182 (2010).
9. Kwak, B., Mulhaupt, F., Myit, S., Mach, F. Statins as a newly recognized type of immunomodulator. Nat Med 6, 1399-1402, doi: 10.1038/82219 (2000).
10. Liappis, A. P., Kan, V. L., Rochester, C. G., Simon, G. L. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33, 1352-1357, doi: 10.1086/323334 (2001).
11. Thomsen, R. W. et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 34, 1080-1086, doi: 10.1097/01.CCM.0000207345.92928.E4 (2006).
12. Li, Z. H., Ramakrishnan, S., Striepen, B., Moreno, S. N. Toxoplasma gondii relies on both host and parasite isoprenoids and can be rendered sensitive to atorvastatin. PLoS Pathog 9, e1003665, doi: 10.1371/journal.ppat.1003665 (2013).
13. Parihar, S. P. et al. Simvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting Listeriainduced phagosomal escape. PLoS One 8, e75490, doi: 10.1371/journal.pone.0075490 (2013).
14. Parihar, S. P. et al. Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 209, 754-763, doi: 10.1093/infdis/jit550 (2014).
15. Kuckelhaus, C. S., Kuckelhaus, S. A., Muniz-Junqueira, M. I. Influence of long-term treatment with pravastatin on the survival, evolution of cutaneous lesion and weight of animals infected by Leishmania amazonensis. Exp Parasitol 127, 658-664, doi: 10.1016/j. exppara.2010.12.003 (2011).
16. Kuckelhaus, C. S., Kuckelhaus, S. A., Tosta, C. E., Muniz-Junqueira, M. I. Pravastatin modulates macrophage functions of Leishmania (L.) amazonensis-infected BALB/c mice. Exp Parasitol 134, 18-25, doi: 10.1016/j.exppara.2013.01.020 (2013).
17. Ghosh, J. et al. Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol. J Lipid Res 53, 2560-2572, doi: 10.1194/jlr.M026914 (2012).
18. Rub, A. et al. Cholesterol depletion associated with Leishmania major infection alters macrophage CD40 signalosome composition and effector function. Nat Immunol 10, 273-280, doi: 10.1038/ni.1705 (2009).
19. Schuster, S., Hartley, M. A., Tacchini-Cottier, F., Ronet, C. A scoring method to standardize lesion monitoring following intradermal infection of Leishmania parasites in the murine ear. Front Cell Infect Microbiol 4, 67, doi: 10.3389/fcimb.2014.00067 (2014).
20. Murray, H. W. Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. J Exp Med 153, 1302-11315 (1981).
21. Desjardins, M., Descoteaux, A. Inhibition of phagolysosomal biogenesis by the Leishmania lipophosphoglycan. J Exp Med 185, 2061-2068 (1997).
22. Pinheiro, R. O. et al. Induction of autophagy correlates with increased parasite load of Leishmania amazonensis in BALB/c but not C57BL/6 macrophages. Microbes Infect 11, 181-190, doi: 10.1016/j.micinf.2008.11.006 (2009).
23. Wang, C. C. et al. Topical simvastatin promotes healing of Staphylococcus aureus-contaminated cutaneous wounds. Int Wound J, doi: 10.1111/iwj.12431 (2015).
24. Thangamani, S. et al. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Sci Rep 5, 16407, doi: 10.1038/srep16407 (2015).
25. Suzuki-Banhesse, V. F. et al. Effect of atorvastatin on wound healing in rats. Biol Res Nurs 17, 159-168, doi: 10.1177/1099800414537348 (2015).
26. Montalvetti, A., Pena-Diaz, J., Hurtado, R., Ruiz-Perez, L. M., Gonzalez-Pacanowska, D. Characterization and regulation of Leishmania major 3-hydroxy-3-methylglutaryl-CoA reductase. The Biochemical journal 349, 27-34 (2000).
27. Nyilasi, I. et al. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol Lett 307, 175-184, doi: 10.1111/j.1574-6968.2010.01972.x (2010).
28. Qiao, J., Kontoyiannis, D. P., Wan, Z., Li, R., Liu, W. Antifungal activity of statins against Aspergillus species. Med Mycol 45, 589-593, doi: 10.1080/13693780701397673 (2007).
29. Fowler, D. M. et al. Suppression of statin effectiveness by copper and zinc in yeast and human cells. Mol Biosyst 7, 533-5544, doi: 10.1039/c0mb00166j (2011).
30. Murray, H. W., Nathan, C. F. In vivo killing of intracellular visceral Leishmania donovani by a macrophage-targeted hydrogen peroxide-generating system. J Infect Dis 158, 1372-1375 (1988).
31. Hurdayal, R. et al. Deletion of IL-4 receptor alpha on dendritic cells renders BALB/c mice hypersusceptible to Leishmania major infection. PLoS Pathog 9, e1003699, doi: 10.1371/journal.ppat.1003699 (2013).
32. Guler, R. et al. PKCdelta regulates IL-12p40/p70 production by macrophages and dendritic cells, driving a type 1 healer phenotype in cutaneous leishmaniasis. Eur J Immunol 41, 706-715, doi: 10.1002/eji.201040985 (2011).